Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.
- March 31, 2023
This symposium shows how rapid diagnostic technology-based assays can be successfully incorporated into antimicrobial stewardship programs. The FDA-cleared T2Bacteria® and T2Candida® Panels provide clinicians with accurate species-specific diagnostic results in 3 to 5 hours directly from a 4 mL whole blood sample – without the wait for blood culture. The T2Bacteria and T2Candida Panels have demonstrated high specificity (>98%) in studies covering over 3,000 patients in more than 15 institutions. They can detect 90% of the most prevalent and common ESKAPE pathogens, enabling faster targeted therapy for patients with bloodstream infections. With exceptionally high negative predictive values (NPV) throughout a hospital – typically 98- 99% or more – the Panels have proven to provide stewardship teams the confidence to safely de-escalate empiric therapy and spare negative side effects for patients.